Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jeffrey D. Ahlers, Igor M. Belyakov, Elaine K. Thomas, Jay A. Berzofsky
Published in Volume 108, Issue 11
J Clin Invest. 2001; 108(11):1677–1685 doi:10.1172/JCI13463
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 6

Blocking both B7-1 and B7-2 on DCs inhibits the CTL response. BALB.A10 DC cultures (2.5 × 10 6) conditioned for 24 hours with Th cells and peptide, T1, or T1(A) (0.5 μM), or no peptide, were depleted of CD4+ cells, pulsed for 1 hour with the CTL epitope P18IIIB (0.5 μM), irradiated, and added to 5 × 106 negatively selected splenic CD8+ cells from BALB.A10 mice primed 1 month earlier subcutaneously with PCLUS 3-18IIIB (20 nmol). (a) DCs conditioned with Th cell and T1(A) elicited higher levels of CTL than DCs conditioned with either Th cells and T1 or no peptide, or overnight treatment with trimeric murine CD40L (3 μg/ml). Lytic activity was determined on day 7 in a 5-hour 51Cr assay on 0.5 μM P18IIIB-pulsed P815 target cells (E/T = 10:1). (b) DCs were conditioned with Th cells and T1(A) (0.5 μM) for 24 hours and CD4+ cells removed. Cells were pulsed for 1.5 hours with P18IIIB, irradiated, and used to stimulate immune CD8+ cells. Anti–B7-1/B7-2 (15 μg/ml each), anti–IL-12 (15 μg/ml), anti-CCR5 (10 μg/ml), or anti-41BBL (10 μg/ml) were added to pulsed DCs at the initiation of CTL culture and on day 3. Similar results were obtained in two additional experiments.